Conclusion: Weekly laboratory monitoring was associated with therapy modifications and documented ADRs in a small number of patients receiving beta-lactam agents as OPAT. This supports current guideline recommendations for laboratory monitoring, even for beta-lactam agents, which are considered relatively safer. Further investigation into the cost-effectiveness of this approach is warranted.

Disclosures: Russell J. Benefield, PharmD, Merck and Co (Grant/Research Support); Paratek Pharmaceuticals (Grant/Research Support); Rempex Pharmaceuticals (Grant/Research Support)

603. Evaluating the Effects of Centers for Medicare & Medicaid Services Sepsis Core Measure in a Community Hospital
So Kim, PharmD1; Peter Ty, PharmD2; Fountain Valley Regional Hospital, BUENA PARK, California

Session: P-23. Clinical Practice Issues

Background: Sepsis is the leading cause of morbidity and mortality in hospitals, accounting for 30% of deaths in the emergency department. In 2001, Rivers et al. found that early goal-directed therapy (EGDT) led to significant mortality benefits, which ultimately prompted United States Centers for Medicare and Medicaid Services (CMS) to mandate EGDT in hospitals through its implementation of sepsis core measures. CMS core measures are intended to facilitate the broad implementation of evidence-based treatment standards, and while voluntary, non-compliance is associated with negative consequences to both quality and financial metrics for participating hospitals. However, while quality measures are implemented to ultimately improve patient care, its effects on the healthcare system can also include negative unanticipated consequences. This study seeks to characterize the effect of the CMS sepsis core measure on sepsis identification, antimicrobial utilization, and specific prescribing patterns.

Methods: This is a retrospective cohort review of 175 randomly selected patients greater than or equal to 18 years of age with admission diagnosis of sepsis, severe sepsis, and septic shock from January 2013 to December 2018. Medical charts were reviewed for relevant data.

Results: Comparing ED antibiotic prescribing patterns between pre- and post-CMS Core Measure timeframes, there was a statistical difference in total antibiotic usage and the initiation of broad antibiotics. There was a decreased time to the first antibiotic, an increase in receiving Normal saline boluses post-CMS Core Measures.

Conclusion: No significant changes were seen in ED antibiotic prescribing behaviors, with regard to volume and spectrum

ED time to antibiotic administration was significantly faster after the implementation of CMS Core Measures. Also, there was a significant positive shift in time to fluid bolus, fluid selection, and fluid volume

Significantly decreased ICU length of stay after implementation of CMS Core Measures possibly associated with above behavior changes

No outcomes benefits (mortality, hospital length of stay) realized after implementation of CMS Core Measures

Disclosures: All Authors: No report disclosures

604. Factors Associated with Adverse Drug Reactions Leading to Discontinuation of Vancomycin in Outpatient Parenteral Antimicrobial Therapy
Josh McDonald, PharmD1; Russell J. Benefield, PharmD2; Laura Certain, MD, PhD3; 1University of Utah Health, Salt Lake City, Utah; 2University of Utah, Salt Lake City, Utah

Session: P-23. Clinical Practice Issues

Background: Over 250,000 patients receive outpatient parenteral antimicrobial therapy (OPAT) in the United States each year. Vancomycin is commonly used in OPAT but has a high rate of discontinuations due to adverse drug reactions (ADRs). Being able to predict the occurrence of these ADRs and assess their impact could improve the overall quality of OPAT services when utilizing vancomycin.

Methods: This was a retrospective chart review of all adult University of Utah Health (UHH) patients who received vancomycin OPAT and had planned follow-up with UHH infectious disease (ID) providers between October 25, 2018 and July 31, 2019. Patients were excluded if they were less than 18 years of age, pregnant, did not have planned follow up with UHH ID physicians, or were on any form of inpatient replacement therapy. The primary outcome assessed was discontinuation of vancomycin due to ADR, as documented by the ID provider. Type of ADR leading to discontinuation and 30-day unplanned readmission were also assessed.

Results: One hundred fifty-eight patients met inclusion criteria (n=158). The mean age of patients was 55 years with a median Charlson comorbidity score of 3. Most patients utilized a non-UHH infusion service (116, 73% vs 42, 27%) and utilized vancomycin as their sole antibiotic (83, 53%). The majority of patients were being treated for orthopedic infections (78, 49%). Twenty-eight patients discontinued vancomycin OPAT due to an ADR (18%). The most common ADR leading to discontinuation was acute kidney injury (10, 36%). Variables associated with ADRs leading to discontinuation included utilization of UHH home infusion services (54% vs 21%, P < 0.001) and initial vancomycin plasma concentrations obtained less than 7 days after discharge (92% vs 71%, P < 0.001). The overall 30 day readmission rate was 10% and the rate among patients who experienced an ADR leading to discontinuation was higher than those who did not (25% vs 8%, P < 0.001).

Conclusion: The overall rate of discontinuation of vancomycin OPAT due to ADR in the UUH population is similar to what has been described in previous literature. The higher rate of unplanned readmission in the population of patients who experienced ADRs warrants further study. The results of this study will be utilized for future quality improvement interventions at our institution.

Disclosures: Russell J. Benefield, PharmD, Merck and Co (Grant/Research Support); Paratek Pharmaceuticals (Grant/Research Support); Rempex Pharmaceuticals (Grant/Research Support)

605. Factors Underlying Antifungal Price Trends in the United States
Christine Thomas, DO1; Whitney Shae, BS2; Devin Koesterl, PhD2; Terese DeFor, MD1; Nathan Bahr, MD, MD1; Jonathan Alpern, MD1; Loyola University Medical Center, Maywood, IL; University of Kansas Medical Center, Kansas City, Kansas; HealthPartners Institute, Bloomington, Minnesota

Session: P-23. Clinical Practice Issues

Background: Antifungal drugs are used to treat conditions ranging from topical dermatologic disease to life-threatening systemic infections. Given their widespread use, understanding factors that affect antifungal pricing will help clinical and policy makers make decisions. The purpose of this study was to identify factors associated with price trends among antifungal drugs.

Methods: Antifungal drug products available in the United States were identified using the Food and Drug Administration (FDA) Orange Book database. Multiple characteristics related to how a drug may be priced were identified using a variety of sources, including the number of FDA indications (IBMC Idronex), quantity of professional guideline recommendations and use as prophylaxis (Infectious Diseases Society of America guidelines for treatment of fungal infections), and route of administration. Wholesale acquisition cost per unit was identified for each drug from the list of drugs listed through 2019 in the Medispan and First Databank databases. Statistical analysis was performed using R (version 3.6.3). Price trajectories over time were constructed using Fisher’s Exact Test and Likelihood Ratio Tests. All tests were conducted at the 5% level of significance.

Results: The majority (n=116) of antifungal drugs were characterized by moderate price increase and an additional n=6 exhibited extreme price increases over time. Few (n=16) were stable. Associations were identified between drug characteristics and extreme price increase cluster membership. These included a fewer number of FDA indications (p<0.0028) and atypical route of administration (p=0.0025). No association was identified between cluster membership and quantity of guideline recommendations, or use as prophylaxis.

Conclusion: Nearly 90% of antifungal drugs exhibited at least moderate price increases over time. Extreme price increases were associated with a fewer number of FDA indications and atypical route of administration.

Disclosures: All Authors: No report disclosures

606. HIV Homecare: Understanding its Impact for Lost-to-Follow-Up Populations
Lily Bonadonna, MD candidate1; Esther Guerrero, BS Candidate2; Tammie McClendon, NP3; Sheronda Union, MA; Dana Kabbani, MD3; Jennifer Veleman, MD, MPH; Wayne State University School of Medicine, Detroit, Michigan; Wayne State University, Detroit, Michigan

Session: P-23. Clinical Practice Issues

Background: Maintaining people living with HIV (PLWH) in clinical care is a global priority. In the metrop-Detroit area of Michigan, approximately 30% of PLWH are out of care. To re-engage lost-to-follow-up patients, the Wayne State University Physician Group – Infectious Disease clinic launched an innovative Homecare program in 2017. In addition to home healthcare delivery, the program included links to community resources and quarterly community meetings. In the first year of Homecare, 28 of 34 participants became virally suppressed at least once. We aimed to understand reasons why people who left clinic-based treatment were able to become virally suppressed in this program. We included data from PLWH and their healthcare providers.

Methods: We used a mixed-methods design, including (1) semi-structured interviews with PLWH and healthcare workers, and (2) a validated Likert scale questionnaire rating illness perception before and after Homecare. Data were collected from 15 PLWH in metro-Detroit and two healthcare workers responsible for program delivery. Semi-structured interviews focused on obstacles to clinic-based care, support networks, and illness perceptions. Interview data were transcribed and analyzed using a grounded theory approach. A fully coded analysis was used to create a conceptual framework of factors contributing to Homecare’s success. Means in eight categories of the brief illness perception questionnaire (BIPQ) were compared using paired t-tests.

Results: The Homecare program offered (1) social support and stigma reduction through strong relationships with healthcare workers; (2) removal of physical and financial barriers such as transportation; and (3) positive changes in illness perception. PLWH worked towards functional coping strategies, including improvements in emotional regulation, acceptance of their diagnosis, and more positive perspectives of control. BIPQ showed significant changes in six domains before and after Homecare.